← Back to Search

Other

ADX-629 for Atopic Dermatitis

Phase 2
Waitlist Available
Research Sponsored by Aldeyra Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Mild, moderate, or severe atopic dermatitis, defined as an IGA score of ≥2 at Baseline
Be older than 18 years old
Must not have
Presence of clinically significant kidney disease or an estimated gloverular filtration rate (eGFR) of less than or equal to 45 milliliters/min/1.73 m2 during screening
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from day 1 to day 90
Awards & highlights
No Placebo-Only Group

Summary

This trial tests the safety and effectiveness of a new drug to treat adults with atopic dermatitis.

Who is the study for?
This trial is for adults over 18 with mild to severe atopic dermatitis, which they've had for at least six months. Participants must not be pregnant or breastfeeding and should agree to use effective contraception during the trial. People with unstable chronic diseases, significant health abnormalities, or serious kidney disease are excluded.
What is being tested?
The study is testing ADX-629's safety and effectiveness in treating atopic dermatitis both alone and alongside standard care. It's a Phase 2 trial involving multiple centers where all participants will openly receive the treatment without being compared to a control group.
What are the potential side effects?
Specific side effects of ADX-629 aren't listed here, but generally, treatments like this could cause skin reactions, irritation or discomfort at the application site if topical, as well as potential systemic effects depending on how it works in the body.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My skin condition is diagnosed as atopic dermatitis with a severity score of 2 or more.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My kidney function is low, with an eGFR of 45 ml/min/1.73m^2 or less.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from day 1 to day 90
This trial's timeline: 3 weeks for screening, Varies for treatment, and from day 1 to day 90 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Adverse Event (AE) Query
Secondary study objectives
Investigator Global Assessment (IGA) Score

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: ADX-629Experimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ADX-629 (Open-label)
2023
Completed Phase 2
~10

Find a Location

Who is running the clinical trial?

Aldeyra Therapeutics, Inc.Lead Sponsor
33 Previous Clinical Trials
4,670 Total Patients Enrolled

Media Library

ADX-629 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05717920 — Phase 2
Atopic Dermatitis Research Study Groups: ADX-629
Atopic Dermatitis Clinical Trial 2023: ADX-629 Highlights & Side Effects. Trial Name: NCT05717920 — Phase 2
ADX-629 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05717920 — Phase 2
~3 spots leftby Jan 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top